Multiple myeloma with acute light chain cast nephropathy.

Multiple myeloma with acute light chain cast nephropathy.
复制标题

DOI:
10.1038/s41408-023-00806-w
复制
发表时间:
2023-03-29
影响因子:
12.8
通讯作者:
Rajkumar, S. Vincent
Rajkumar, S. Vincent
中科院分区:
医学1区
文献类型:
--
作者:
Leung, Nelson;Rajkumar, S. Vincent

文献摘要

参考文献

被引文献

相似文献

轻链管型肾病(LCCN)是多发性骨髓瘤(MM)患者急性肾损伤(阿基)的主要原因,目前被定义为骨髓瘤定义事件。虽然新药物的长期预后有所改善,但LCCN患者的短期死亡率仍显着较高,特别是如果肾衰竭未逆转。肾功能的恢复需要快速和显著减少所涉及的血清游离轻链。因此,对这些患者进行适当的治疗至关重要。在本文中,我们提供了一种治疗患有活检证实的LCCN或已排除阿基其他原因的MM患者的算法。算法尽可能基于随机试验的数据。当试验数据不可用时,我们的建议基于非随机数据和专家对最佳实践的意见。我们建议所有患者在采用我们概述的治疗方案之前,如果可行,应参加临床试验。
Light chain cast nephropathy (LCCN) is a leading cause of acute kidney injury (AKI) in patients with multiple myeloma (MM) and is now defined as a myeloma defining event. While the long-term prognosis has improved with novel agents, short-term mortality remains significantly higher in patients with LCCN especially if the renal failure is not reversed. Recovery of renal function requires a rapid and significant reduction of the involved serum free light chain. Therefore, proper treatment of these patients is of the utmost importance. In this paper, we provide an algorithm for treatment of MM patients who present with biopsy-proven LCCN or in those where other causes of AKI have been ruled out. The algorithm is based on data from randomized trial whenever possible. When trial data is not available, our recommendations is based on non-randomized data and expert opinions on best practices. We recommend that all patients should enroll in a clinical trial if available prior to resorting to the treatment algorithm we outlined.
DOI: 10.1038/bcj.2015.20
发表时间: 2015-03-20
影响因子: 12.8
作者:
Gonsalves WI;Leung N;Rajkumar SV;Dispenzieri A;Lacy MQ;Hayman SR;Buadi FK;Dingli D;Kapoor P;Go RS;Lin Y;Russell SJ;Lust JA;Zeldenrust S;Kyle RA;Gertz MA;Kumar SK
通讯作者: Kumar SK
DOI: 10.1136/bmj.1.6008.503
发表时间: 1976-01-01
影响因子: --
作者:
FEEST, TG;BURGE, PS;COHEN, SL
通讯作者: COHEN, SL
DOI: 10.1016/j.clml.2019.05.010
发表时间: 2019-08-01
影响因子: 2.7
作者:
Ho, P. Joy;Moore, Elizabeth M.;Spencer, Andrew
通讯作者: Spencer, Andrew
DOI: 10.1056/nejmoa2028631
发表时间: 2021-07-01
影响因子: 158.5
作者:
Kastritis, E.;Palladini, G.;Comenzo, R. L.
通讯作者: Comenzo, R. L.
DOI: 10.1002/cncr.20888
发表时间: 2005-03-15
期刊: CANCER
影响因子: 6.2
作者:
Jagannath, S;Barlogie, B;Anderson, KC
通讯作者: Anderson, KC